Endurant Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Endurant Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,454	Closed	-$674K	–	71
2022 Q2	$674K	Buy	+8,454	New	+$801K	0.24%	43
2016 Q4	–	Sell	-26,040	Closed	-$472K	–	102
2016 Q3	$472K	Sell	26,040 -30,400	-54%	-$594K	0.17%	75
2016 Q2	$930K	Sell	56,440 -42,400	-43%	-$686K	0.31%	56
2016 Q1	$1.64M	Buy	98,840 +42,900	+77%	+$751K	0.53%	48
2015 Q4	$1.21M	Sell	55,940 -64,760	-54%	-$1.26M	0.41%	54
2015 Q3	$2.39M	Buy	+120,700	New	+$3.81M	0.8%	41
2015 Q2	–	Sell	-29,700	Closed	-$771K	–	112
2015 Q1	$771K	Buy	+29,700	New	+$544K	0.25%	76

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Endurant Capital Management's HZNP Position: Q3 2022 in Review

Endurant Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 8,454 shares — an estimated $674K sold.

Endurant Capital Management first reported a position in HZNP in Q1 2015 and held it in 7 quarters. The position peaked at $2.39M in Q3 2015. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Endurant Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Endurant Capital Management sold 8,454 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $674K.
Endurant Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 7 quarters.
Endurant Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.39M in Q3 2015.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.